WESTFORD, Mass., March 15, 2011 /PRNewswire/ — Cynosure, Inc.
(Nasdaq:
CYNO), a leader in laser- and light-based treatments for
minimally invasive and non-invasive aesthetic applications, today
announced that two of its newest workstations for laser-assisted
lipolysis and non-invasive cellulite reduction have received key
international regulatory clearances.
Health Canada has issued a Medical Device License authorizing
the sale in Canada of the company’s SmoothShapes® XV system for
the temporary reduction in the appearance of cellulite. The
non-invasive SmoothShapes XV treats cellulite through a proprietary
process known as Photomology®, which combines laser and light
energy with mechanical manipulation (vacuum and massage) to produce
tighter, smoother-looking skin.
Overseas, the Korea Food and Drug Administration has granted
marketing approval to Cynosure’s Smartlipo Triplex™, the
company’s minimally invasive technology for fat removal and skin
tightening. The system uses Cynosure’s patented MultiPlex
technology to combine three wavelengths – 1064 nm, 1320 nm
and 1440 nm – in one laser output. MultiPlex technology
enables multiple wavelengths to be fired sequentially, creating a
blended thermal and photomechanical effect that efficiently
liquefies fat and tightens skin through tissue coagulation.
Cynosure plans to sell the products through its direct sales
force in North America and Korea.
SmoothShapes XV and Smartlipo Triplex are also cleared for
marketing in the United States by the U.S. Food and Drug
Administration. Additionally, SmoothShapes XV is CE marked for sale
in the European Union.
“SmoothShapes XV and Smartlipo Triplex are treatments that we
believe deliver a superior outcome for the high-volume aesthetic
applications they serve,” said Michael Davin, president and chief
executive officer of Cynosur
‘/>”/>
SOURCE